Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice

The main goal of this research was the evaluation of the efficacy of amphot ericin B (AMB) in comparison with AMB-Intralipid (AMB-IL) admixtures in cyc lophosphamide (CY)-compromised animals for the treatment of systemic candid osis induced by several pathogenic Candida spp. Four-week-old ICR female mi ce were inoculated ip with 200 mg/kg of CY. At day 4 post-CY treatment the animals were inoculated iv with Candida albicans, Candida glabrata or Candi da tropicalis (different inocula for the different species). Forty-eight ho urs later various doses of conventional AMB (0.4-1 mg/kg for 5 days) or AMB -IL admixtures (0.4-2 mg/kg for 5 days) were administered iv and the surviv al rate and mean survival time (MST) were evaluated during an observation p eriod of up to 42 days. These experiments showed that while all control ani mals died, the survival rate of the AMB-treated mice ranged between 13 and 65% and that of the AMB-IL-treated mice was In the range 30-100% depending on the infecting dose and Candida species. The follow-up of the course of i nfection showed that AMB-IL admixtures increased the survival time of the t reated mice. The MST was significantly higher for the mice treated with AMB -IL than for those treated with conventional AMB and was especially marked in the groups treated with high doses of the drug. Hence, the data obtained in the present study show that in CY-compromised mice AMB-IL admixtures we re very effective in the treatment of systemic candidosis caused by C. albi cans and non-albicans species.